Testing a new drug combined with radiation for brain tumors
Development of the brain penetrant ATM inhibitor WSD0628 in combination with radiation for recurrent high grade glioma
This study is looking at a new drug called WSD0628 to see if it can help make radiation therapy work better for patients with recurrent high-grade gliomas, like glioblastoma, while keeping side effects low.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-10929435 on NIH RePORTER |
What this research studies
This research investigates the use of a new drug, WSD0628, that can penetrate the brain and enhance the effectiveness of radiation therapy for patients with recurrent high-grade gliomas, such as glioblastoma. The study aims to evaluate the safety and efficacy of this drug in combination with radiation, building on promising pre-clinical results that suggest it can improve tumor control without increasing harmful side effects in the central nervous system. Patients will be monitored for their response to treatment and any potential side effects.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with recurrent high-grade gliomas who have undergone prior treatments.
Not a fit: Patients with low-grade gliomas or those who have not been diagnosed with gliomas may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with high-grade gliomas, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promising results with similar approaches, indicating potential for success in this novel application.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Sarkaria, Jann N. — Mayo Clinic Rochester
- Study coordinator: Sarkaria, Jann N.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.